Adult cancer patients survive longer in the Netherlands: 5-Year survival rate increased by 12% between 1989-1993 and 2004-2008;Volwassen kankerpatiënten overleven langer in Nederland: 5-Jaarsoverleving 12% toegenomen tussen 1989-1993 en 2004-2008

Nederlands Tijdschrift voor Geneeskunde

Volumn 155, Issue 12, 2011, Pages 514-521

  Siesling, Sabine ^a   Visser, Otto ^b   Luth, Trienika K ^a   Karim Kos, Henrike E ^d   Van De Poll Franse, Lonneke V ^e   Aben, Katja K H ^a   Damhuis, Ronald A M ^c  

^a Locatie Enschede/Groningen   (Netherlands)

^b Afdeling Onderzoek   (Netherlands)

^c Afd Registratie en Onderzoek   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Eindhoven   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER SURVIVAL; NETHERLANDS; REVIEW; SURVIVAL RATE;

EID: 79953900505     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Wassink WF. Vooruitgang in de behandeling van kwaadaardige gezwellen. I. Algemene inleiding. Ned Tijdschr Geneeskd. 1959;103:17-24.
2. Janssen-Heijnen ML, Louwman WJ, van de Poll-Franse LV, Voogd AC, Houterman S, Coebergh JW. Trends in incidentie en prevalentie van kanker en in overleving van patiënten in Zuidoost-Nederland, 1970-1999. Ned Tijdschr Geneeskd. 2003;147:1118-26.
3. Schouten LJ, Jager JJ, van den Brandt PA. Quality of cancer registry data: a comparison of data provided by clinicians with those of registration personnel. Br J Cancer. 1993;68:974-7. (Pubitemid 23315233)
4. Hakulinen T, Abeywickrama KH. A computer program package for relative survival analysis. Comput Programs Biomed. 1985;19:197-207. (Pubitemid 15098487)
5. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40:2307-16. (Pubitemid 39348882)
6. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23:51-64.
7. Coebergh JWW, Verhagen-Teulings MT, Crommelin MH, van der Heijden LH, Hop WCJ. De overlevingskansen bij patiënten met kanker gediagnostiseerd in 1975-1985 in Zuidoost-Noord-Brabant en Noord-Limburg. Ned Tijdschr Geneeskd. 1991;135:938-43.
8. Cremers RG, Karim-Kos HE, Houterman S, Verhoeven RH, Schröder FH, van der Kwast TH. il PJ, Coebergh JW, Kiemeney LA. Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989-2006. Eur J Cancer. 2010;46:2077-87.
9. Van Steenbergen LN, Elferink MA, Krijnen P, et al; Working Group Output of The Netherlands Cancer Registry. Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006. Ann Oncol. 2010;21:2206-12.
10. Wouters MW, Karim-Kos HE, le Cessie S, et al. Centralization of esophageal cancer surgery: does it improve clinical outcome? Ann Surg Oncol. 2009;16:1789-98.
11. Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E. Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer. 2010;46:160-9.
12. Joosse A, de Vries E, Eckel R, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2011;131:719-26.
13. Rosso S, Gondos A, Zanetti R, et al. Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: The role of screening and a comparison with data from the United States. Eur J Cancer. 2010;46:3351-7.
14. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;100:1780-91.
15. Visser O, van Leeuwen FE. Stage specific survival of epithelial cancers in North-Holland/Flevoland, The Netherlands. Eur J Cancer. 2005;41:2321-30.
16. Martijn H, Voogd AC, van de Poll-Franse LV, Repelaer van Driel OJ, Rutten HJ, Coebergh JW. Improved survival of patients with rectal cancer since 1980: a population-based study. Eur J Cancer. 2003;39:2073-9.
17. Peeters KC, Kapiteijn E. van d, V. Managing rectal cancer: the Dutch experience. Colorectal Dis. 2003;5:423-6.
18. Gardner GJ, Jewell EL. Current and future directions of clinical trials for ovarian cancer. Cancer Control. 2011;18:44-51.
19. Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol. 2011;18:89-97.
20. Aguayo A, Couban S. State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment. Leuk Lymphoma. 2009;50(Suppl 2):1-8..
21. Maloney D, Morschhauser F, Linden O, Hagenbeek A, Gisselbrecht C. Diversity in antibody-based approaches to non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(Suppl 1):20-27..
22. Janssen-Heijnen ML, Houtenman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW. Prognostic Impact of increasing agell and co-morbidity in cancer patients: a population based approach. Crit Rev Oncol Hematol. 2005;55:231-40. (Pubitemid 41222320)
23. Karim-Kos HE. de VE, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345-89.
24. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009;45:931-91.
25. Van de Schans SA, Gondos A, van Spronsen DJ, et al. Improving relative survival, but large remaining differences in survival for non-Hodgkin's lymphoma across Europe and the United States from 1990 to 2004. J Clin Oncol. 2011;29:192-9.
26. Brenner H, Hakulinen T. Implications of incomplete registration of deaths on long-term survival estimates from population-based cancer registries. Int J Cancer. 2009;125:432-7.
27. Guadagnolo BA, Liu CC, Cormier JN, Du XL. Evaluation of trends in the use of intensity-modulated radiotherapy for head and neck cancer from 2000 through 2005: socioeconomic disparity and geographic variation in a large population-based cohort. Cancer. 2010;116:3505-12.
28. Signaleringscommissie Kanker van KWF kankerbestrijding. Kanker in Nederland. Trends, prognoses en implicaties voor zorgvraag. Den Haag: KWF kankerbestrijding; 2004.
29. Harteloh P, de Bruin K, Kardaun J. The reliability of cause-of-death coding in The Netherlands. Eur J Epidemiol. 2010;25:531-8.